Total Debt to Capital: G1 Pharma (GTHX)

G1 Therapeutics, Inc. (GTHX) specializes in developing bone marrow preservation agents for chemotherapy, ensuring stable demand regardless of market cycles. This chart illustrates the total debt-to-equity ratio, which stands at 2.08. Strong brand authority among oncologists drives loyalty, while stringent FDA requirements and patent protection create significant barriers to entry for new players.

G1 Therapeutics Inc. (GTHX): Debt to Equity Ratio from 07/04/2022 to 09/28/2024

G1 Therapeutics - analytical breakdowns and key metrics (GTHX)

- share price and consensus valuation forecast:

Stock Price G1 Therapeutics Inc.|GTHX - Analyst Target Range

- company stock exchange capitalization indicators:

Market Capitalization G1 Therapeutics|GTHX - Total Enterprise Value

- book capitalization indicators:

Net Assets per Single Share G1 Therapeutics|GTHX - Accounting Capitalization|Market Capitalization to Book Value Ratio g1therapeutics.com|GTHX - Company Assets

- issuer credit burden and liquidity indicators:

- net income and valuation ratios data:

GTHX - Company Net Income

Basic company analysis:GTHX, G1 Therapeutics, Inc.

The total debt-to-equity ratio isolates the fundamental stability of G1 Therapeutics, Inc. (GTHX) from market volatility by measuring the proportion of borrowed funds within the financing structure relative to equity. By analyzing the company's financial leverage dynamics, an investor assesses the default risk, which is critical for a company with a proprietary drug whose pricing power is limited by the slow adoption of the product into hospital formularies.

Key competitors